27 results on '"Hegenbart, Ute"'
Search Results
2. Comparison of IGLV2‐14 light chain sequences of patients with AL amyloidosis or multiple myeloma.
- Author
-
Berghaus, Natalie, Schreiner, Sarah, Poos, Alexandra M., Raab, Marc S., Goldschmidt, Hartmut, Mai, Elias K., Salwender, Hans‐Jürgen, Bernhard, Helga, Thurner, Lorenz, Müller‐Tidow, Carsten, Weinhold, Niels, Hegenbart, Ute, Schönland, Stefan O., and Huhn, Stefanie
- Subjects
MULTIPLE myeloma ,AMYLOIDOSIS ,IMMUNOGLOBULIN light chains ,ISOELECTRIC point - Abstract
Light chain amyloidosis (AL) is one of the most common forms of systemic amyloidosis and is caused by the deposition of insoluble fibrils derived from misfolded and aggregated immunoglobulin light chains (LC). To uncover the causes leading to this aggregation, we compared AL LC sequences with those of patients with the related disease multiple myeloma (MM), which do not aggregate in insoluble fibrils in vivo. IGLV2‐14 is one of the most common AL‐associated IGLV subfamilies. Here, we analysed IGLV2‐14 LC sequences of 13 AL and eight MM patients in detail. We found that AL‐associated LCs presented a lower median mutation count (7.0 vs. 11.5 in MM; P = 0.045), as well as an overall composition of less charged amino acids than MM LCs. However, we did not find a mutation that was present in ≥ 50% of the AL and not in the MM sequences. Furthermore, we did not find a significant difference in the isoelectric point (pI) in general, suggesting similar stability of the LCs in AL and MM. However, the subgroup of patients without a detectable heavy chain stood out. Surprisingly, they are characterized by an increase in mutation count (median 7.0 vs. 5.5) and pI (median 7.82 vs. 6.44, P = 0.043). In conclusion, our data suggest that the amount of mutations and the introduction of charges play a crucial role in AL fibril formation, as well as the absence or presence of a potential heavy chain binding partner. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Initial experience with transcatheter tricuspid valve repair in patients with cardiac amyloidosis.
- Author
-
Hoerbrand, Isabel A., Volz, Martin J., Aus dem Siepen, Fabian, Aurich, Matthias, Schlegel, Philipp, Geis, Nicolas A., Hegenbart, Ute, Konstandin, Mathias H., Frey, Norbert, and Raake, Philip W.
- Subjects
TRICUSPID valve insufficiency ,TRICUSPID valve ,CARDIAC amyloidosis ,TRICUSPID valve surgery ,CARDIAC patients ,HEART failure patients ,TRANSTHYRETIN - Abstract
Aims: Wildtype transthyretin amyloid cardiomyopathy is an under‐recognized cause of heart failure in elderly patients. Transcatheter tricuspid valve repair is a newly emerging therapeutic option for severe tricuspid regurgitation (TR). We present first insights into safety and possible benefits of this procedure in patients with cardiac amyloidosis. Methods and results: Eight patients with cardiac non‐hereditary (wildtype) transthyretin (ATTRwt) amyloidosis and severe to torrential TR, undergoing successful transcatheter tricuspid valve repair, were included in the analysis and compared to a control group of 21 patients without cardiac amyloidosis. All patients presented with an advanced stage of amyloid cardiomyopathy. Primary endpoint was reduction in TR at 3 months follow‐up. Secondary endpoints were feasibility, safety, hospitalization or death, clinical improvement, cardiac biomarkers, and structural and functional right heart parameter obtained by echocardiography. Transcatheter tricuspid valve repair resulted in a significant reduction of TR (IV to II, P = 0.008) in all eight patients with cardiac amyloidosis (100%). Device success (amyloidosis 75% vs. control group 86%, P = 0.597) and overall probability of hospitalization or death (amyloidosis 13% vs. control group 25%, P = 0.646) were similar compared with those in the control group at 3 months follow‐up. Transcatheter tricuspid valve repair led to an improvement of New York Heart Association functional class (P = 0.031) and 6 min walking distance (from 313 ± 118 to 337 ± 106, P = 0.012). TR reduction in amyloidosis patients was less extensive compared with that in control group (TR‐reduction 1.6 ± 0.3, P = 0.008 vs. control group 2.3 ± 0.3, P < 0.0001). Furthermore, these patients showed no significant improvement of structural right heart parameters. Conclusions: Transcatheter tricuspid valve repair is a safe and feasible new treatment option in patients with amyloid cardiomyopathy and has the potential to improve TR‐grade and clinical status. However, the benefit appears to be less pronounced compared with patients without cardiac amyloidosis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Statin‐based endothelial prophylaxis and outcome after allogeneic stem cell transplantation.
- Author
-
Pabst, Caroline, Schreck, Nicholas, Benner, Axel, Hegenbart, Ute, Schönland, Stefan, Radujkovic, Aleksandar, Schmitt, Michael, Müller‐Tidow, Carsten, Orsatti, Laura, Dreger, Peter, and Luft, Thomas
- Subjects
STEM cell transplantation ,HEMATOPOIETIC stem cell transplantation ,ENDOTHELIUM diseases ,INDOLEAMINE 2,3-dioxygenase ,ADVERSE health care events ,ENZYME metabolism - Abstract
Background: Allogeneic haematopoietic stem cell transplantation (alloSCT) often remains the only curative therapy for hematologic malignancies. Although the management of transplant‐associated adverse events considerably improved over the last decades, nonrelapse mortality (NRM) remains a challenge, and endothelial dysfunction was identified as a major contributor to NRM. Methods: Statin‐based endothelial prophylaxis (SEP) has been implemented in the standard of care in our transplant centre to reduce NRM caused by endothelial injury. Here, we retrospectively analysed the impact of SEP on clinical outcome in a cohort of 347 alloSCT patients. Results: SEP (n = 209) was associated with significantly reduced NRM (hazard ratio 0.61, 95% CI 0.38–0.96) and better overall survival (OS) after acute graft‐versus‐host disease (HR 0.59, 95% CI 0.37–0.93). Subgroup analyses showed that the NRM benefit was mainly found in patients with an intermediate endothelial activation and stress index (EASIX), while relapse risk was not affected. On day 100 post‐alloSCT, patients receiving SEP had significantly higher levels of the rate‐limiting enzyme of tryptophan metabolism, indoleamine 2,3‐dioxygenase (IDO), higher kynurenine to tryptophan ratios as a proxy of IDO activity and tended to have lower levels of the endothelial injury marker ST2 (p =.055). No significant differences in interferon‐gamma or IL18 levels were observed. These biomarker signatures suggest that the beneficial effects of SEP might be mediated by both endothelial protection and immunomodulation. Conclusions: Together, these data suggest that SEP improves NRM and OS post‐alloSCT in particular in patients with intermediate endothelial risk and provide first mechanistic clues about its potential mode of action. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Concurrent light chain amyloidosis and proximal tubulopathy: Insights into different aggregation behavior—A case report.
- Author
-
Feurstein, Simone, Zoller, Julian, Schwab, Constantin, Schreiner, Sarah, Mundt, Heiko, Breitkreutz, Iris, Schneider, Brigitte, Beimler, Jörg, Zeier, Martin, Waldherr, Rüdiger, Gröschel, Stefan, Müller‐Tidow, Carsten, Schönland, Stefan O., and Hegenbart, Ute
- Published
- 2022
- Full Text
- View/download PDF
6. Challenges in the Management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic
- Author
-
MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Kastritis, Efstathios, Wechalekar, Ashutosh, Schönland, Stefan, Sanchorawala, Vaishali, Merlini, Giampaolo, Palladini, Giovanni, Minnema, Monique, Roussel, Murielle, Jaccard, Arnaud, Hegenbart, Ute, Kumar, Shaji, Cibeira, Maria Teresa, Blade, Joan, Dimopoulos, Meletios A, MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Kastritis, Efstathios, Wechalekar, Ashutosh, Schönland, Stefan, Sanchorawala, Vaishali, Merlini, Giampaolo, Palladini, Giovanni, Minnema, Monique, Roussel, Murielle, Jaccard, Arnaud, Hegenbart, Ute, Kumar, Shaji, Cibeira, Maria Teresa, Blade, Joan, and Dimopoulos, Meletios A
- Published
- 2020
7. Submyeloablative total body irradiation‐based conditioning and allogeneic stem cell transplantation in high‐risk myeloma with early progression after up‐front autologous transplantation.
- Author
-
Mai, Elias K., Schmitt, Thomas, Radujkovic, Aleksandar, König, Laila, Goldschmidt, Hartmut, Ho, Anthony D., Luft, Thomas, Müller‐Tidow, Carsten, Dreger, Peter, Hegenbart, Ute, and Schönland, Stefan O.
- Subjects
STEM cell transplantation ,AUTOTRANSPLANTATION ,ACUTE diseases ,MULTIPLE myeloma ,HEMATOPOIETIC stem cell transplantation ,GRAFT versus host disease - Abstract
Finally, other potential treatment options to reduce relapse/progression post alloSCT include post-transplantation cyclophosphamide (ptCy). Keywords: myeloma therapy; stem cell transplantation; cytogenetics EN myeloma therapy stem cell transplantation cytogenetics 244 248 5 12/27/21 20220101 NES 220101 Treatment of patients with relapsed multiple myeloma (MM) after autologous stem cell transplantation (autoSCT) remains challenging. Consequently, a future goal in MM therapy is to combine modern treatment concepts and alloSCT in suitable patients to reduce disease burden and enhance disease control in patients with relapsed high-risk MM. Details on re-induction treatment and response rates prior to alloSCT, engraftment and post alloSCT response rates, maintenance therapy, donor lymphocyte infusions (DLI) and relapse therapies are shown in Table I. The median age at alloSCT was 50 (range 34-64) years. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
8. Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow‐up.
- Author
-
Basset, Marco, Kimmich, Christoph R., Schreck, Nicholas, Krzykalla, Julia, Dittrich, Tobias, Veelken, Kaya, Goldschmidt, Hartmut, Seckinger, Anja, Hose, Dirk, Jauch, Anna, Müller‐Tidow, Carsten, Benner, Axel, Hegenbart, Ute, and Schönland, Stefan O.
- Subjects
LENALIDOMIDE ,PROGNOSIS ,OVERALL survival ,SURVIVAL rate ,AMYLOIDOSIS - Abstract
Summary: Lenalidomide and dexamethasone (RD) is a standard treatment in relapsed/refractory immunoglobulin light chain (AL) amyloidosis (RRAL). We retrospectively investigated toxicity, efficacy and prognostic markers in 260 patients with RRAL. Patients received a median of two prior treatment lines (68% had been bortezomib‐refractory; 33% had received high‐dose melphalan). The median treatment duration was four cycles. The 3‐month haematological response rate was 31% [very good haematological response (VGHR) in 18%]. The median follow‐up was 56·5 months and the median overall survival (OS) and haematological event‐free survival (haemEFS) were 32 and 9 months. The 2‐year dialysis rate was 15%. VGHR resulted in better OS (62 vs. 26 months, P < 0·001). Cardiac progression predicted worse survival (22 vs. 40 months, P = 0·027), although N‐terminal prohormone of brain natriuretic peptide (NT‐proBNP) increase was frequently observed. Multivariable analysis identified these prognostic factors: NT‐proBNP for OS [hazard ratio (HR) 1·71; P < 0·001]; gain 1q21 for haemEFS (HR 1·68, P = 0·014), with a trend for OS (HR 1·47, P = 0·084); difference between involved and uninvolved free light chains (dFLC) and light chain isotype for OS (HR 2·22, P < 0·001; HR 1·62, P = 0·016) and haemEFS (HR 1·88, P < 0·001; HR 1·59, P = 0·008). Estimated glomerular filtration rate (HR 0·71, P = 0·004) and 24‐h proteinuria (HR 1·10, P = 0·004) were prognostic for renal survival. In conclusion, clonal and organ biomarkers at baseline identify patients with favourable outcome, while VGHR and cardiac progression define prognosis during RD treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement.
- Author
-
Oubari, Sara, Naser, Eyad, Papathanasiou, Maria, Luedike, Peter, Hagenacker, Tim, Thimm, Andreas, Rischpler, Christoph, Kessler, Lukas, Kimmich, Christoph, Hegenbart, Ute, Schönland, Stefan, Rassaf, Tienush, Reinhardt, Hans Christian, Jöckel, Karl‐Heinz, Dürig, Jan, Dührsen, Ulrich, and Carpinteiro, Alexander
- Subjects
CARDIAC amyloidosis ,OVERALL survival ,DIAGNOSIS ,PHYSICIANS ,TREATMENT effectiveness ,SYMPTOMS - Abstract
Objective: To study the impact of time to diagnosis on cardiac Mayo stages, treatment outcome, and overall survival. Methods: We retrospectively analyzed 77 consecutive patients diagnosed between 2015 and 2020 with AL amyloidosis and cardiac involvement. Medical history was recorded in standardized form with the help of a questionnaire. Results: Time from onset of symptoms of cardiac failure to diagnosis was correlated with the severity of cardiac involvement in modified Mayo 2004 and revised Mayo 2012 staging systems (rs = 0.30, 95% CI: 0.07‐0.50, P =.007 and rs = 0.25, 95% CI: 0.01‐0.45, P =.03). Patients with advanced Mayo 2004 stages received reduced‐intensity regimens and had a lower probability to achieve adequate hematologic‐ and cardiac response after first‐line treatment than patients with early stages (rs = 0.28, 95% CI: 0.04‐0.48, P =.01 and rs = 0.72, 95% CI: 0.55‐0.82, P <.0001) and poorer overall survival (P =.0004). Compared with patients diagnosed within the first year, patients diagnosed after 13‐18 or ≥19 months from first symptoms had a 3‐ to 5 times higher risk of dying. Our data indicate that there is a 12‐month window within which the diagnosis of AL amyloidosis needs to be established to avoid early deterioration and death. Conclusions: Sensitizing physicians and raising awareness for the disease are crucial for timely diagnosis and may improve the outcome of the disease. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Daratumumab, lenalidomide, and dexamethasone in systemic light‐chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21.
- Author
-
Kimmich, Christoph R., Terzer, Tobias, Benner, Axel, Hansen, Timon, Carpinteiro, Alexander, Dittrich, Tobias, Veelken, Kaya, Jauch, Anna, Huhn, Stefanie, Basset, Marco, Goldschmidt, Hartmut, Müller‐Tidow, Carsten, Schönland, Stefan O., and Hegenbart, Ute
- Published
- 2021
- Full Text
- View/download PDF
11. Initial experience with percutaneous mitral valve repair in patients with cardiac amyloidosis.
- Author
-
Volz, Martin J., Pleger, Sven T., Weber, Andreas, Geis, Nicolas A., Hamed, Sonja, Mereles, Derliz, Hegenbart, Ute, Katus, Hugo A., Frey, Norbert, Raake, Philip W., and Kreusser, Michael M.
- Subjects
CARDIAC amyloidosis ,MITRAL valve ,CARDIAC patients ,MITRAL valve insufficiency ,HEART failure patients - Abstract
Background: Percutaneous mitral valve repair (PMVR) is a therapeutic option for severe mitral regurgitation (MR) in patients with heart failure due to differential aetiologies. However, only little is known about the safety and efficacy of this procedure in patients with amyloid cardiomyopathy. Methods: Five patients with cardiac amyloidosis and moderate to severe or severe MR undergoing PMVR were analysed retrospectively and compared to seven patients with cardiac amyloidosis and severe MR without intervention. Clinical and functional data, renal function and cardiac biomarkers as well as established risk scores for cardiac amyloidosis were assessed. Primary endpoint was the reduction in MR one year after PMVR. Secondary endpoints were safety, overall mortality after 12 months compared with the control group, as well as changes in clinical and functional parameters. Results: Amyloidosis risk assessment documented amyloid cardiomyopathy at an advanced stage in all patients. Procedural, technical and device success of PMVR were all 100% and residual MR remained mild to moderate at 12 months follow‐up (P =.038 vs before PMVR). Differences in survival compared with the control (no PMVR) group pointed to a possible survival benefit in the PMVR group (P =.02). Conclusion: PMVR is a feasible and safe procedure in patients with cardiac amyloidosis and might carry a possible survival benefit in this patient group. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
12. Targeting transthyretin ‐ Mechanism‐based treatment approaches and future perspectives in hereditary amyloidosis.
- Author
-
Dohrn, Maike F., Ihne, Sandra, Hegenbart, Ute, Medina, Jessica, Züchner, Stephan L., Coelho, Teresa, and Hahn, Katrin
- Subjects
TRANSTHYRETIN ,DOXYCYCLINE ,SMALL interfering RNA ,SMALL molecules ,AMYLOIDOSIS ,CARRIER proteins - Abstract
The liver‐derived, circulating transport protein transthyretin (TTR) is the cause of systemic hereditary (ATTRv) and wild‐type (ATTRwt) amyloidosis. TTR stabilization and knockdown are approved therapies to mitigate the otherwise lethal disease course. To date, the variety in phenotypic penetrance is not fully understood. This systematic review summarizes the current literature on TTR pathophysiology with its therapeutic implications. Tetramer dissociation is the rate‐limiting step of amyloidogenesis. Besides destabilizing TTR mutations, other genetic (RBP4, APCS, AR, ATX2, C1q, C3) and external (extracellular matrix, Schwann cell interaction) factors influence the type of onset and organ tropism. The approved small molecule tafamidis stabilizes the tetramer and significantly decelerates the clinical course. By sequence‐specific mRNA knockdown, the approved small interfering RNA (siRNA) patisiran and antisense oligonucleotide (ASO) inotersen both significantly reduce plasma TTR levels and improve neuropathy and quality of life compared to placebo. With enhanced hepatic targeting capabilities, GalNac‐conjugated siRNA and ASOs have recently entered phase III clinical trials. Bivalent TTR stabilizers occupy both binding groves in vitro, but have not been tested in trials so far. Tolcapone is another stabilizer with the potential to cross the blood–brain barrier, but its half‐life is short and liver failure a potential side effect. Amyloid‐directed antibodies and substances like doxycycline aim at reducing the amyloid load, however, none of the yet developed antibodies has successfully passed clinical trials. ATTR‐amyloidosis has become a model disease for pathophysiology‐based treatment. Further understanding of disease mechanisms will help to overcome the remaining limitations, including application burden, side effects, and blood–brain barrier permeability. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. P899: HOVON 104; LONG TERM FOLLOW‐UP OF AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER BORTEZOMIB INDUCTION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED AL AMYLOIDOSIS.
- Author
-
Minnema, Monique, Nasserinejad, Kazem, Hegenbart, Ute, Ypma, Paula, Lung Wu, Ka, José Kersten, Marie, Croockewit, Sandra, de Waal, Esther, Zweegman, Sonja, Tick, Lidwien, Broijl, Annemiek, and Schönland, Stefan
- Published
- 2023
- Full Text
- View/download PDF
14. Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression.
- Author
-
Basset, Marco, Hummedah, Kamal, Kimmich, Christoph, Veelken, Kaya, Dittrich, Tobias, Brandelik, Simone, Kreuter, Michael, Hassel, Jessica, Bosch, Nikolaus, Stuhlmann‐Laeisz, Christiane, Blank, Norbert, Müller‐Tidow, Carsten, Röcken, Christoph, Hegenbart, Ute, and Schönland, Stefan
- Published
- 2020
- Full Text
- View/download PDF
15. Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID‐19 pandemic.
- Author
-
Kastritis, Efstathios, Wechalekar, Ashutosh, Schönland, Stefan, Sanchorawala, Vaishali, Merlini, Giampaolo, Palladini, Giovanni, Minnema, Monique, Roussel, Murielle, Jaccard, Arnaud, Hegenbart, Ute, Kumar, Shaji, Cibeira, Maria T., Blade, Joan, and Dimopoulos, Meletios A.
- Subjects
CARDIAC amyloidosis ,COVID-19 pandemic ,COVID-19 ,RESPIRATORY infections ,HYPOTENSION ,HEALTH services accessibility - Abstract
Summary: The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)‐associated coronavirus disease 2019 (COVID‐19) is primarily manifested as a respiratory tract infection, but may affect and cause complications in multiple organ systems (cardiovascular, gastrointestinal, kidneys, haematopoietic and immune systems), while no proven specific therapy exists. The challenges associated with COVID‐19 are even greater for patients with light chain (AL) amyloidosis, a rare multisystemic disease affecting the heart, kidneys, liver, gastrointestinal and nervous system. Patients with AL amyloidosis may need to receive chemotherapy, which probably increases infection risk. Management of COVID‐19 may be particularly challenging in patients with AL amyloidosis, who often present with cardiac dysfunction, nephrotic syndrome, neuropathy, low blood pressure and gastrointestinal symptoms. In addition, patients with AL amyloidosis may be more susceptible to toxicities of drugs used to manage COVID‐19. Access to health care may be difficult or limited, diagnosis of AL amyloidosis may be delayed with detrimental consequences and treatment administration may need modification. Both patients and treating physicians need to adapt in a new reality. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
16. Magnetization transfer ratio quantifies polyneuropathy in hereditary transthyretin amyloidosis.
- Author
-
Kollmer, Jennifer, Hegenbart, Ute, Kimmich, Christoph, Hund, Ernst, Purrucker, Jan C., Hayes, John M., Lentz, Stephen I., Sam, Georges, Jende, Johann M. E., Schönland, Stefan O., Bendszus, Martin, Heiland, Sabine, and Weiler, Markus
- Subjects
- *
MAGNETIZATION transfer , *SCIATIC nerve , *NEUROLOGIC examination , *PERIPHERAL nervous system , *AMYLOIDOSIS - Abstract
Objective: To quantify peripheral nerve lesions in symptomatic and asymptomatic hereditary transthyretin amyloidosis with polyneuropathy (ATTRv‐PNP) by analyzing the magnetization transfer ratio (MTR) of the sciatic nerve, and to test its potential as a novel biomarker for macromolecular changes. Methods: Twenty‐five patients with symptomatic ATTRv‐PNP, 30 asymptomatic carriers of the mutant transthyretin gene (mutTTR), and 20 age‐/sex‐matched healthy controls prospectively underwent magnetization transfer contrast imaging at 3 Tesla. Two axial three‐dimensional gradient echo sequences with and without an off‐resonance saturation rapid frequency pulse were conducted at the right distal thigh. Sciatic nerve regions of interest were manually drawn on 10 consecutive axial slices in the images without off‐resonance saturation, and then transferred to the corresponding slices that were generated by the sequence with the off‐resonance saturation pulse. Subsequently, the MTR and cross‐sectional area (CSA) of the sciatic nerve were evaluated. Detailed neurologic and electrophysiologic examinations were conducted in all ATTRv‐PNP patients and mutTTR‐carriers. Results: Sciatic nerve MTR and CSA reliably differentiated between ATTRv‐PNP, mutTTR‐carriers, and controls. MTR was lower in ATTRv‐PNP (26.4 ± 0.7; P < 0.0001) and in mutTTR‐carriers (32.6 ± 0.8; P = 0.0005) versus controls (39.4 ± 2.1), and was also lower in ATTRv‐PNP versus mutTTR‐carriers (P = 0.0009). MTR correlated negatively with the NIS‐LL and positively with CMAPs and SNAPs. CSA was higher in ATTRv‐PNP (34.3 ± 1.7 mm3) versus mutTTR‐carriers (26.0 ± 1.1 mm3; P = 0.0005) and versus controls (20.4 ± 1.2 mm3; P < 0.0001). CSA was also higher in mutTTR‐carriers versus controls. Interpretation: MTR is a novel imaging marker that can quantify macromolecular changes in ATTRv‐PNP and differentiate between symptomatic ATTRv‐PNP and asymptomatic mutTTR‐carriers and correlates with electrophysiology. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
17. Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma.
- Author
-
Kriegsmann, Katharina, Dittrich, Tobias, Neuber, Brigitte, Awwad, Mohamed H. S., Hegenbart, Ute, Goldschmidt, Hartmut, Hillengass, Jens, Hose, Dirk, Seckinger, Anja, Müller‐Tidow, Carsten, Ho, Anthony D., Schönland, Stefan, and Hundemer, Michael
- Published
- 2018
- Full Text
- View/download PDF
18. CD7 is expressed on a subset of normal CD34‐positive myeloid precursors.
- Author
-
Kriegsmann, Katharina, Löffler, Harald, Eckstein, Volker, Schulz, Renate, Kräker, Sandra, Braun, Ute, Luft, Thomas, Hegenbart, Ute, Schönland, Stefan, Dreger, Peter, Krämer, Alwin, Ho, Anthony D., Müller‐Tidow, Carsten, and Hundemer, Michael
- Subjects
TUMORS ,FLOW cytometry ,CHIMERISM ,STEM cell transplantation ,BONE marrow - Abstract
Abstract: Objective: To improve monitoring of myeloid neoplasms by flow cytometry‐based minimal residual disease (MRD) analysis, we analyzed the significance of leukemia‐associated immunophenotype (LAIP) markers in 44 patients. Methods: In a pilot study cohort, peripheral blood or bone marrow samples from 13 patients with myeloid neoplasms and one case of B lymphoblastic leukemia in complete hematologic remission after allogeneic bone marrow or stem cell transplantation were subjected to selection for leukemia‐specific phenotypes by fluorescence‐activated cell sorting using individual marker combinations, followed by PCR‐based chimerism analysis. Results: The feasibility of this method could be demonstrated, with selection being successful in 12 cases, including two cases where mixed chimerism was found exclusively in sorted cells. Interestingly, four specimens displayed full donor chimerism in cells expressing the presumably aberrant combination CD34
+ /CD7+ . Further analyses, including assessment of an independent cohort of 25 patients not affected by neoplastic bone marrow infiltration, revealed that normal myeloid precursors usually include a population coexpressing CD34, CD13, CD33, and CD7. Conclusion: We conclude that the combination CD34+ /CD7+ might not be suitable as an LAIP for MRD diagnostics and that a subset of normal myeloid precursors in the bone marrow expresses CD7. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
19. Cerebral amyloidoma is characterized by B‐cell clonality and a stable clinical course.
- Author
-
Heß, Katharina, Purrucker, Jan, Hegenbart, Ute, Brokinkel, Benjamin, Berndt, Rouven, Keyvani, Kathy, Monoranu, Camelia M., Löhr, Mario, Reifenberger, Guido, Munoz‐Bendix, Christopher, Kalla, Jörg, Groß, Justus, Schick, Uta, Kollmer, Jennifer, Klapper, Wolfram, Röcken, Christoph, Hasselblatt, Martin, and Paulus, Werner
- Subjects
B cells ,CLONING ,AMYLOIDOSIS ,IMMUNOHISTOCHEMISTRY ,PATHOLOGY - Abstract
Abstract: Amyloidomas are rare amyloid‐containing lesions, which may also occur in the central nervous system. Etiology, pathogenesis and clinical course are poorly understood. To gain more insight into the biology of cerebral amyloidoma, they aimed to characterize its histopathological, molecular and clinical features in a retrospective series of seven patients. FFPE tissue specimens were examined using immunohistochemistry, chromogenic
in situ hybridization (CISH) for light chains kappa and lambda as well as an IgH gene clonality analysis. Follow‐up information was gathered by reviewing patient records and imaging results. Median age of the three males and four females was 50 years (range: 35–53 years). All cerebral amyloidomas were located supratentorially and were classified as lambda light chain amyloidosis (AL‐λ;n = 6) and kappa light chain amyloidosis (AL‐κ;n = 1) on immunohistochemistry and CISH. B‐cell clonality was confirmed by IgH gene clonality assay in all cases examined. After a median follow‐up of 21 months, all patients were alive and showed stable disease. No progression to systemic disease was observed. In conclusion, their data suggest that cerebral amyloidoma is a local disease characterized by B‐cell clonality and associated with a stable clinical course. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
20. Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice.
- Author
-
Baertsch, Marc‐Andrea, Hillengass, Jens, Blocka, Joanna, Schönland, Stefan, Hegenbart, Ute, Goldschmidt, Hartmut, Raab, Marc S., and Baertsch, Marc-Andrea
- Subjects
ENZYME inhibitors ,HYDROXY acids ,INDOLE compounds ,PHARMACODYNAMICS ,THERAPEUTICS - Abstract
The histone deacetylase inhibitor panobinostat has shown efficacy in phase-II and phase-III trials for multiple myeloma and has recently received market approval in combination with bortezomib and dexamethasone. Here, we retrospectively report our single center experience with panobinostat/bortezomib/dexamethasone (FVD) in a heavily pretreated patient population (n = 24) with a high degree of refractoriness to proteasome inhibitors (PI) and immunomodulatory drugs (IMiD). Median age was 67 years (range 49-87) and the median number of prior therapies was 5 (range 2-17). Fourteen patients (58%) had high-risk cytogenetic aberrations. Thirteen (54%) and 21 (88%) patients were refractory to PIs and IMiDs, respectively. Twelve patients (50%) were refractory to bortezomib and 7 (29%) to carfilzomib; 6 patients (25%) were refractory to both bortezomib and carfilzomib. In 21 patients evaluable for response, overall response rate (ORR; ≥PR) was 33% (7/21) and 81% (17/21) achieved at least stable disease. Median progression-free survival (PFS) and overall survival were 3.5 and 9.8 months, respectively. Significant differences between bortezomib-sensitive and -refractory patients were observed. In bortezomib-sensitive patients, median PFS was 6.3 months compared to 2.3 months in bortezomib-refractory patients (P < .001). Median overall survival was not reached vs 4.8 months (P = .046) in bortezomib-sensitive and bortezomib-refractory patients, respectively. The only patient refractory to carfilzomib but sensitive to bortezomib achieved very good partial remission and PFS of 6.3 months, suggesting discrete mechanisms of resistance to different PIs. As expected, thrombocytopenia and fatigue/asthenia occurred in nearly all patients (96% and 83%, respectively). Diarrhea was observed in only 19% of patients which compares favorably with the high rates of diarrhea reported in the PANORAMA trials. With panobinostat dose reductions in 67% of patients, FVD was tolerated by the majority of patients. In conclusion, FVD showed efficacy in a heavily pretreated, high-risk multiple myeloma population with a high degree of patients refractory to novel agents including PIs. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
21. Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial.
- Author
-
Scheffold, Annika, Jebaraj, Billy Michael Chelliah, Jaramillo, Sonia, Tausch, Eugen, Steinbrecher, Daniela, Hahn, Michael, Böttcher, Sebastian, Ritgen, Matthias, Bunjes, Donald, Zeis, Matthias, Stadler, Michael, Uharek, Lutz, Scheid, Christoph, Hegenbart, Ute, Hallek, Michael, Kneba, Michael, Schmitz, Norbert, Döhner, Hartmut, Dreger, Peter, and Stilgenbauer, Stephan
- Subjects
LYMPHOCYTIC leukemia ,STEM cell transplantation ,TELOMERES ,STEM cell treatment ,CHROMOSOMES ,LEUKEMIA treatment ,THERAPEUTICS - Abstract
The article reports on a study which investigated the impact of telomere length on the outcome of allogeneic stem cell transplantation (SCT) for patients with poor risk chronic lymphocytic leukaemia (CLL) based on the German CLL3X trial which included 100 patients. Topics covered include association of telomere length with clinical characteristics, and analysis of telomere length using quantitative polymerase chain reaction.
- Published
- 2017
- Full Text
- View/download PDF
22. Common Fibril Structures Imply Systemically Conserved Protein Misfolding Pathways In Vivo.
- Author
-
Annamalai, Karthikeyan, Liberta, Falk, Vielberg, Marie-Theres, Close, William, Lilie, Hauke, Gührs, Karl-Heinz, Schierhorn, Angelika, Koehler, Rolf, Schmidt, Andreas, Haupt, Christian, Hegenbart, Ute, Schönland, Stefan, Schmidt, Matthias, Groll, Michael, and Fändrich, Marcus
- Subjects
AMYLOIDOSIS ,AMYLOID beta-protein precursor ,MOLECULAR structure ,POST-translational modification ,PROTEIN folding - Abstract
Systemic amyloidosis is caused by the misfolding of a circulating amyloid precursor protein and the deposition of amyloid fibrils in multiple organs. Chemical and biophysical analysis of amyloid fibrils from human AL and murine AA amyloidosis reveal the same fibril morphologies in different tissues or organs of one patient or diseased animal. The observed structural similarities concerned the fibril morphology, the fibril protein primary and secondary structures, the presence of post-translational modifications and, in case of the AL fibrils, the partially folded characteristics of the polypeptide chain within the fibril. Our data imply for both analyzed forms of amyloidosis that the pathways of protein misfolding are systemically conserved; that is, they follow the same rules irrespective of where inside one body fibrils are formed or accumulated. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
23. Potential therapeutic targets in plasma cell disorders: A flow cytometry study.
- Author
-
Lisenko, Katharina, Schönland, Stefan, Hegenbart, Ute, Wallenwein, Katrin, Braun, Ute, Mai, Elias K., Hillengass, Jens, Goldschmidt, Hartmut, Jauch, Anna, Ho, Anthony D., Raab, Marc, and Hundemer, Michael
- Published
- 2017
- Full Text
- View/download PDF
24. Flow cytometry-based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis.
- Author
-
Lisenko, Katharina, Schönland, Stefan O., Jauch, Anna, Andrulis, Mindaugas, Röcken, Christoph, Ho, Anthony D., Goldschmidt, Hartmut, Hegenbart, Ute, and Hundemer, Michael
- Subjects
PLASMA cell diseases ,DIAGNOSIS of blood diseases ,AMYLOIDOSIS diagnosis ,FLOW cytometry ,HISTOPATHOLOGY ,TREATMENT effectiveness ,DIAGNOSIS - Abstract
Systemic amyloid light chain ( AL) amyloidosis is a life-threatening protein deposition disorder; however, effective therapy can dramatically improve the prognosis of AL patients. Therefore, accurate diagnosis of the underlying hematologic disease is important. Multi-parameter flow cytometry ( MFC) is a reliable method to analyze lymphatic neoplasias and to detect even a small lymphatic clone. We analyzed the presence of clonal plasma cell ( PC) and B cells in the bone marrow of 63 patients with newly diagnosed AL amyloidosis by MFC. We compared the results with the levels of monoclonal protein, the histopathology and cytogenetic results. As reference of light chain restriction, we used the immunohistochemical results of κ or λ positive amyloid deposits in various tissues. MFC identified underlying clonal lymphatic cells in all but two patients (61 of 63, 97%). Sixty-one patients harbored malignant PCs, whereas B-cell lymphomas were identified in two patients. Furthermore, MFC indicated at least one putative immunotherapeutical target ( CD20, CD38, CD52, or SLAMF7) on malignant PCs in all but one patient. These results demonstrate that MFC is a reliable tool for an accurate diagnosis of the underlying hematologic disease and the detection of potential immunotherapeutical targets in patients with AL amyloidosis. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
25. Polymorphism of Amyloid Fibrils In Vivo.
- Author
-
Annamalai, Karthikeyan, Gührs, Karl-Heinz, Koehler, Rolf, Schmidt, Matthias, Michel, Henri, Loos, Cornelia, Gaffney, Patricia M., Sigurdson, Christina J., Hegenbart, Ute, Schönland, Stefan, and Fändrich, Marcus
- Subjects
IN vivo studies ,AMYLOID ,POLYPEPTIDES ,PARKINSON'S disease ,GENETIC polymorphisms ,IN vitro studies - Abstract
Polymorphism is a wide-spread feature of amyloid-like fibrils formed in vitro, but it has so far remained unclear whether the fibrils formed within a patient are also affected by this phenomenon. In this study we show that the amyloid fibrils within a diseased individual can vary considerably in their three-dimensional architecture. We demonstrate this heterogeneity with amyloid fibrils deposited within different organs, formed from sequentially non-homologous polypeptide chains and affecting human or animals. Irrespective of amyloid type or source, we found in vivo fibrils to be polymorphic. These data imply that the chemical principles of fibril assembly that lead to such polymorphism are fundamentally conserved in vivo and in vitro. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
26. Polymorphismus von Amyloidfibrillen in vivo.
- Author
-
Annamalai, Karthikeyan, Gührs, Karl ‐ Heinz, Koehler, Rolf, Schmidt, Matthias, Michel, Henri, Loos, Cornelia, Gaffney, Patricia M., Sigurdson, Christina J., Hegenbart, Ute, Schönland, Stefan, and Fändrich, Marcus
- Abstract
Copyright of Angewandte Chemie is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2016
- Full Text
- View/download PDF
27. Seroconversion Rates After the Second COVID-19 Vaccination in Patients With Systemic Light Chain (AL) amyloidosis.
- Author
-
Liebers, Nora, Schönland, Stefan O., Speer, Claudius, Edelmann, Dominic, Schnitzler, Paul, Kräusslich, Hans-Georg, Mueller-Tidow, Carsten, Hegenbart, Ute, and Dietrich, Sascha
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.